This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Original article
Jarr, K.-U. et al. The pleiotropic benefits of statins include the ability to reduce CD47 and amplify the effect of pro-efferocytic therapies in atherosclerosis. Nat. Cardiovasc. Res. 1, 253–262 (2022)
Related article
Engelen, S. E. et al. Therapeutic strategies targeting inflammation and immunity in atherosclerosis: how to proceed? Nat. Rev. Cardiol. https://doi.org/10.1038/s41569-021-00668-4 (2022)
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Fernández-Ruiz, I. Statins promote efferocytosis in atherosclerotic plaques. Nat Rev Cardiol 19, 286 (2022). https://doi.org/10.1038/s41569-022-00699-5
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41569-022-00699-5
This article is cited by
-
The Role of Macrophages in Atherosclerosis: Participants and Therapists
Cardiovascular Drugs and Therapy (2023)
-
Efferocytosis: a double-edged sword in microbial immunity
Archives of Microbiology (2023)